Safety And Efficacy Study Of CP-675,206 In HIV-Infected Patients
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if CP-675,206, a monoclonal antibody to CTLA4, is
safe and well-tolerated, reduces viral load, and improves immune function in patients
infected with HIV.